Diabetes Mellitus: A Comprehensive Guide to Differential Diagnosis and Management

Introduction

Diabetes mellitus (DM), a pervasive chronic metabolic disorder, is defined by persistent hyperglycemia stemming from defects in insulin secretion, insulin action, or both. The global impact of diabetes is staggering, with hundreds of millions affected worldwide and projections indicating a continued rise in prevalence. The ramifications of chronic hyperglycemia, compounded by other metabolic disturbances inherent in DM, extend to systemic organ damage. This damage precipitates debilitating and life-threatening complications, notably microvascular (retinopathy, nephropathy, and neuropathy) and macrovascular diseases, dramatically escalating the risk of cardiovascular events. While the diagnosis of diabetes itself has become increasingly refined, the differential diagnosis of diabetes remains a critical aspect of clinical practice. Accurate differentiation from other conditions presenting with similar symptoms or metabolic derangements is crucial for appropriate patient management and to avoid misdiagnosis. This article provides an in-depth exploration of diabetes mellitus, with a particular focus on its differential diagnosis, alongside its pathophysiology, clinical presentation, and management strategies. Understanding the nuances of Diabetes Differential Diagnosis is paramount for healthcare professionals to ensure optimal patient outcomes and to implement targeted therapeutic interventions.

Etiology of Diabetes Mellitus and Overlapping Conditions

Diabetes mellitus is broadly categorized into type 1 diabetes (T1DM), type 2 diabetes (T2DM), gestational diabetes mellitus (GDM), and less common forms such as monogenic and secondary diabetes. Each type has distinct etiologies, which must be considered when formulating a differential diagnosis if patients present with signs and symptoms suggestive of diabetes.

Type 1 Diabetes Mellitus (T1DM) vs. Latent Autoimmune Diabetes in Adults (LADA)

T1DM, accounting for a minority of diabetes cases, is characterized by autoimmune-mediated destruction of pancreatic beta cells, leading to absolute insulin deficiency. Genetic predisposition and environmental triggers are implicated in its pathogenesis. While typically diagnosed in childhood or adolescence, T1DM can manifest at any age.

Differential Diagnosis Point: Latent autoimmune diabetes in adults (LADA) is often considered within the diabetes differential diagnosis, particularly in adults initially diagnosed with T2DM who are lean and fail oral hypoglycemic agents. LADA shares autoimmune features with T1DM but progresses more slowly. Distinguishing LADA from T2DM is crucial as LADA patients will eventually require insulin therapy, similar to T1DM. Autoantibody testing (GAD, IA-2, and ICA) can aid in differentiating LADA from T2DM.

Type 2 Diabetes Mellitus (T2DM) and Metabolic Syndrome

T2DM, the most prevalent form, is marked by insulin resistance and progressive beta-cell dysfunction. Initially, insulin resistance is compensated by increased insulin production, but over time, beta-cell failure leads to hyperglycemia. Obesity, sedentary lifestyles, and unhealthy diets are major risk factors.

Differential Diagnosis Point: Metabolic syndrome (Syndrome X) shares significant overlap with T2DM, often preceding or coexisting with it. Metabolic syndrome is characterized by insulin resistance, abdominal obesity, dyslipidemia, and hypertension. While metabolic syndrome increases the risk of T2DM, it is not diabetes itself. The differential diagnosis lies in the degree of hyperglycemia. Patients with metabolic syndrome may have impaired glucose tolerance or impaired fasting glucose, but not necessarily meet the diagnostic criteria for diabetes. However, the presence of metabolic syndrome should prompt close monitoring for the development of T2DM.

Gestational Diabetes Mellitus (GDM) vs. Pre-existing Diabetes in Pregnancy

GDM is defined as hyperglycemia first detected during pregnancy, typically in the second or third trimester. It complicates a significant percentage of pregnancies and increases the future risk of T2DM for both mother and offspring.

Differential Diagnosis Point: It is essential to differentiate GDM from pre-existing diabetes (T1DM or T2DM) diagnosed before pregnancy. Screening for GDM is usually performed at 24-28 weeks of gestation. However, women with risk factors for pre-existing diabetes should be screened earlier in pregnancy or even preconceptionally. The differential diagnosis is based on the timing of diagnosis relative to pregnancy onset and may influence management strategies. For example, women with pre-existing diabetes require closer glycemic control and preconception planning.

Monogenic and Secondary Diabetes vs. Common Diabetes Types

Monogenic diabetes, caused by single gene mutations, includes neonatal diabetes mellitus and maturity-onset diabetes of the young (MODY). Secondary diabetes arises from other conditions like pancreatic diseases, endocrinopathies, or drug use.

Differential Diagnosis Point: Monogenic diabetes should be considered in the differential diagnosis of diabetes, particularly in young individuals with a strong family history of diabetes but lacking typical T1DM autoimmunity or T2DM risk factors. MODY, for example, often presents before age 25 and may be misdiagnosed as T1DM or T2DM. Genetic testing is crucial for definitive diagnosis and tailored management. Secondary diabetes should be suspected in patients with known pancreatic disease, endocrinopathies (Cushing’s syndrome, acromegaly, pheochromocytoma), or those on medications known to induce hyperglycemia (corticosteroids, antipsychotics). Addressing the underlying cause is paramount in managing secondary diabetes.

Drug-Induced Hyperglycemia as a Key Differential

Drug-induced hyperglycemia is a significant aspect of diabetes differential diagnosis. Several medications can elevate blood glucose levels, mimicking or exacerbating diabetes. Corticosteroids, antipsychotics (especially second-generation), thiazide diuretics, beta-blockers, and certain antiretroviral drugs are among the common culprits.

Differential Diagnosis Point: A thorough medication history is essential in evaluating hyperglycemia. If drug-induced hyperglycemia is suspected, discontinuing the offending medication (if clinically feasible) and monitoring blood glucose levels can help differentiate it from true diabetes. If hyperglycemia persists after medication cessation, further evaluation for diabetes is warranted.

Epidemiology and Risk Factors: Context for Differential Diagnosis

Diabetes is a global epidemic, with prevalence increasing alongside aging populations, urbanization, and lifestyle changes promoting obesity and inactivity. Understanding the epidemiology and risk factors of diabetes provides valuable context for differential diagnosis. For instance, age of onset, family history, ethnicity, and lifestyle factors can help narrow down the possibilities when considering various conditions in the differential.

Pathophysiology: Distinguishing Mechanisms in Differential Diagnosis

The pathophysiology of diabetes varies by type, but all forms ultimately lead to hyperglycemia. Understanding these distinct pathophysiological mechanisms aids in differential diagnosis, particularly when considering conditions that might present with similar metabolic disturbances.

T1DM Pathophysiology and Autoimmune Diseases

T1DM involves autoimmune destruction of pancreatic beta cells. Genetic predisposition, particularly HLA genes, plays a significant role. Autoantibodies (anti-GAD, anti-insulin, etc.) are often detectable, though their diagnostic utility in routine practice is limited after the initial diagnosis.

Differential Diagnosis Point: The presence of autoantibodies is highly suggestive of T1DM or LADA, helping to differentiate these from T2DM, where autoantibodies are typically absent. Furthermore, T1DM patients are more prone to other autoimmune disorders like Addison’s disease, Graves’ disease, and celiac disease. The co-occurrence of these conditions can strengthen the suspicion of an autoimmune etiology in patients presenting with hyperglycemia.

T2DM Pathophysiology and Insulin Resistance Syndromes

T2DM is characterized by insulin resistance and beta-cell dysfunction. Insulin resistance is often linked to obesity, particularly visceral adiposity, which promotes inflammation and adipokine dysregulation. Other factors, such as physical inactivity, genetics, and abnormal incretin biology, contribute to T2DM pathogenesis.

Differential Diagnosis Point: Insulin resistance is central to T2DM and metabolic syndrome. Conditions associated with severe insulin resistance, such as polycystic ovary syndrome (PCOS) and acanthosis nigricans, may present with hyperglycemia or features mimicking T2DM. However, these conditions are distinct entities requiring specific diagnostic and management approaches. The differential diagnosis in these cases involves assessing the overall clinical picture, including reproductive and dermatological features in PCOS and acanthosis nigricans, respectively, alongside metabolic parameters.

History and Physical Examination: Clues for Differential Diagnosis

A thorough history and physical examination are crucial in the initial assessment of patients with suspected diabetes and play a significant role in guiding the differential diagnosis. Classic symptoms of diabetes include polyuria, polydipsia, polyphagia, unexplained weight loss (more common in T1DM), fatigue, and recurrent infections.

Differential Diagnosis Point: While these symptoms are suggestive of diabetes, they are not specific. Conditions like diabetes insipidus can present with polyuria and polydipsia but are due to ADH deficiency or resistance, not hyperglycemia. Psychogenic polydipsia (excessive water drinking) can also mimic diabetes symptoms. The differential diagnosis requires careful evaluation of urine volume, osmolality, and glucose levels to distinguish these conditions from diabetes mellitus.

Neurological symptoms like numbness and tingling (neuropathy) and visual disturbances (blurred vision) can occur in diabetes but also in other conditions. Peripheral neuropathy can be caused by vitamin deficiencies, alcohol abuse, and other neurological disorders. Blurred vision can be due to refractive errors, cataracts, or other ophthalmological conditions. A comprehensive neurological and ophthalmological examination is essential to differentiate diabetic complications from other causes.

Evaluation and Diagnostic Criteria: Refining the Differential

The diagnosis of diabetes relies on standardized criteria using fasting plasma glucose (FPG), 2-hour plasma glucose during an oral glucose tolerance test (OGTT), or glycated hemoglobin (HbA1c). These tests are also used to identify prediabetes.

Differential Diagnosis Point: While these tests are highly sensitive and specific for diagnosing diabetes, certain conditions can affect test results and complicate the differential diagnosis. For example, acute illness or stress can transiently elevate blood glucose, leading to false-positive results if diabetes testing is performed during these periods. HbA1c can be unreliable in conditions affecting red blood cell turnover, such as hemolytic anemia, hemoglobinopathies, and pregnancy. In such cases, alternative diagnostic tests like fructosamine may be considered. Repeat testing in a stable clinical state is often necessary to confirm the diagnosis and rule out transient hyperglycemia.

Differential Diagnosis: A Detailed List and Distinguishing Features

The differential diagnosis of diabetes mellitus encompasses a range of conditions that may present with overlapping signs, symptoms, or laboratory findings. A systematic approach is crucial to accurately differentiate diabetes from these mimics.

1. Drug-Induced Hyperglycemia

• Causative Agents: Corticosteroids, antipsychotics, thiazide diuretics, beta-blockers, immunosuppressants (tacrolimus, cyclosporine), protease inhibitors, niacin, pentamidine.
• Distinguishing Features: Temporal association with medication initiation or dose increase. Hyperglycemia may resolve upon drug discontinuation. Medication history is crucial.

2. Genetic Defects of Beta-Cell Function (MODY, Neonatal Diabetes)

• Conditions: Maturity-Onset Diabetes of the Young (MODY) subtypes (MODY1-14), neonatal diabetes mellitus.
• Distinguishing Features: Strong family history of diabetes, onset often before age 25 (MODY), onset in the first 6 months of life (neonatal diabetes). Lack of typical T1DM autoimmunity or T2DM risk factors. Genetic testing is diagnostic.

3. Genetic Defects in Insulin Action (Insulin Resistance Syndromes)

• Conditions: Severe insulin resistance syndromes (e.g., Rabson-Mendenhall syndrome, Donohue syndrome), lipodystrophies.
• Distinguishing Features: Extreme insulin resistance requiring very high doses of insulin if needed. Often associated with characteristic physical features (e.g., acanthosis nigricans, lipodystrophy). Genetic testing can confirm diagnosis.

4. Diseases of the Exocrine Pancreas (Pancreatitis, Cystic Fibrosis, Pancreatic Cancer, Hemochromatosis)

• Conditions: Chronic pancreatitis, cystic fibrosis-related diabetes (CFRD), pancreatic cancer, hemochromatosis-related diabetes.
• Distinguishing Features: History of pancreatic disease or cystic fibrosis. Pancreatic enzyme insufficiency, malabsorption, or steatorrhea may be present. Imaging studies of the pancreas (CT, MRI) may reveal structural abnormalities. Hemochromatosis may present with iron overload and other organ involvement.

5. Endocrinopathies (Cushing’s Syndrome, Acromegaly, Pheochromocytoma, Hyperthyroidism)

• Conditions: Cushing’s syndrome (hypercortisolism), acromegaly (growth hormone excess), pheochromocytoma (catecholamine excess), hyperthyroidism.
• Distinguishing Features: Clinical features of the specific endocrinopathy (e.g., moon face, buffalo hump in Cushing’s; acral enlargement in acromegaly; episodic hypertension in pheochromocytoma; heat intolerance and tremor in hyperthyroidism). Hormonal assays are diagnostic.

6. Infections (Congenital Rubella, Cytomegalovirus)

• Conditions: Congenital rubella syndrome, congenital cytomegalovirus (CMV) infection.
• Distinguishing Features: Congenital infections may cause beta-cell damage and diabetes in infancy or childhood. History of maternal infection during pregnancy. Other congenital anomalies may be present. Serological testing for rubella or CMV can be helpful.

7. Uncommon Forms of Immune-Mediated Diabetes (“Idiopathic T1DM”)

• Condition: Idiopathic type 1 diabetes (Type 1B).
• Distinguishing Features: Features of T1DM (ketosis-prone) but without evidence of autoimmunity (negative autoantibodies). More common in individuals of African and Asian descent.

8. Other Genetic Syndromes Associated with Diabetes (Down Syndrome, Turner Syndrome, Wolfram Syndrome)

• Conditions: Down syndrome (Trisomy 21), Turner syndrome (45,XO), Wolfram syndrome (DIDMOAD).
• Distinguishing Features: Presence of other features characteristic of the specific genetic syndrome. Karyotyping or genetic testing is diagnostic for the underlying syndrome. Wolfram syndrome is characterized by Diabetes Insipidus, Diabetes Mellitus, Optic Atrophy, and Deafness (DIDMOAD).

9. Diabetes Insipidus

• Conditions: Central diabetes insipidus (ADH deficiency), nephrogenic diabetes insipidus (ADH resistance).
• Distinguishing Features: Polyuria and polydipsia, but urine is dilute (low specific gravity and osmolality). Hypernatremia may be present. Blood glucose levels are normal. Water deprivation test and ADH measurement help differentiate.

10. Renal Glycosuria

• Condition: Renal glycosuria (benign, familial, or secondary to renal disease).
• Distinguishing Features: Glucose in the urine despite normal blood glucose levels. Normal FPG and OGTT. Elevated urine glucose excretion with normal plasma glucose.

11. Stress Hyperglycemia

• Condition: Transient hyperglycemia due to acute stress (surgery, trauma, acute illness).
• Distinguishing Features: Hyperglycemia is typically transient and resolves with resolution of stress. May not meet diagnostic criteria for diabetes in the absence of pre-existing glucose intolerance. Repeat testing after recovery is essential.

12. Gestational Diabetes Mimics (Transient Hyperglycemia of Pregnancy)

• Condition: Transient hyperglycemia during pregnancy that does not meet full GDM criteria.
• Distinguishing Features: Hyperglycemia detected during pregnancy screening but does not meet diagnostic thresholds for GDM. Glucose levels typically normalize postpartum. Repeat testing postpartum to rule out persistent glucose intolerance.

Treatment and Management: Tailoring Therapy After Differential Diagnosis

Once a definitive diagnosis of diabetes mellitus is established, and differential diagnoses have been appropriately excluded, the focus shifts to management. Treatment strategies vary depending on the type of diabetes and individual patient characteristics.

For T1DM, insulin therapy is the cornerstone of management, typically using basal-bolus regimens or insulin pumps. Lifestyle modifications, including diet and exercise, are also crucial.

For T2DM, initial management often involves lifestyle interventions (diet, exercise, weight loss). Metformin is typically the first-line pharmacological agent. Subsequent therapies may include sulfonylureas, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, thiazolidinediones, and insulin, depending on glycemic control and comorbidities. Recent evidence highlights the cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists in patients with T2DM and established cardiovascular disease.

GDM management prioritizes lifestyle modifications, and if glycemic targets are not met, insulin or metformin may be used. Postpartum follow-up and screening for T2DM are essential for women with GDM.

Monogenic diabetes management is tailored to the specific genetic defect. Some forms of MODY may be managed with sulfonylureas, while others may require insulin. Neonatal diabetes may be transient or permanent, with treatment ranging from sulfonylureas to insulin.

Secondary diabetes management focuses on addressing the underlying cause, if possible, alongside glycemic control. For drug-induced hyperglycemia, medication discontinuation or dose reduction may be sufficient.

Prognosis and Complications: Long-Term Implications of Accurate Differential Diagnosis

The prognosis of diabetes mellitus depends on various factors, including glycemic control, adherence to therapy, and management of comorbidities. Poorly controlled diabetes leads to increased risk of microvascular (retinopathy, nephropathy, neuropathy) and macrovascular (cardiovascular disease, peripheral artery disease, cerebrovascular disease) complications.

Accurate differential diagnosis is crucial for appropriate management and preventing long-term complications. Misdiagnosis or delayed diagnosis can lead to suboptimal treatment and increased risk of adverse outcomes. For example, mistaking LADA for T2DM and delaying insulin therapy can result in poor glycemic control and increased risk of ketoacidosis. Failure to recognize secondary diabetes may lead to overlooking treatable underlying conditions.

Early diagnosis, effective management, and comprehensive patient education are essential to mitigate the long-term complications of diabetes and improve patient outcomes.

Deterrence, Patient Education, and Interprofessional Care

Patient education is paramount in diabetes management. Patients need to understand the importance of blood glucose control, lifestyle modifications, self-monitoring of blood glucose, medication adherence, and recognition of hypoglycemia symptoms. Regular eye exams, foot care, and cardiovascular risk factor management are also essential components of diabetes care.

An interprofessional team approach, involving physicians, nurses, dietitians, diabetes educators, pharmacists, and other specialists, is crucial for comprehensive diabetes care. Effective communication and care coordination among team members are essential to optimize patient outcomes and address the multifaceted needs of individuals with diabetes.

Conclusion

Diabetes mellitus is a complex chronic metabolic disorder with significant global health implications. While the diagnosis of diabetes itself is well-defined, the differential diagnosis of diabetes remains a critical clinical skill. A wide range of conditions can mimic diabetes, and accurate differentiation is essential for appropriate patient management. A thorough history, physical examination, targeted laboratory investigations, and consideration of clinical context are crucial in formulating a comprehensive differential diagnosis. By meticulously considering the differential, healthcare professionals can ensure accurate diagnosis, tailored treatment, and improved outcomes for patients presenting with hyperglycemia or symptoms suggestive of diabetes mellitus. Continued research and advancements in diagnostic and therapeutic strategies are essential to further refine our approach to diabetes and its differential diagnosis, ultimately improving the lives of millions affected by this prevalent condition.

References

1. Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018 Feb;14(2):88-98. PubMed: 29219149
2. Malek R, Hannat S, Nechadi A, Mekideche FZ, Kaabeche M. Diabetes and Ramadan: A multicenter study in Algerian population. Diabetes Res Clin Pract. 2019 Apr;150:322-330. PubMed: 30779972
3. Choi YJ, Chung YS. Type 2 diabetes mellitus and bone fragility: Special focus on bone imaging. Osteoporos Sarcopenia. 2016 Mar;2(1):20-24. PMC free article: PMC6372751 PubMed: 30775463
4. Picke AK, Campbell G, Napoli N, Hofbauer LC, Rauner M. Update on the impact of type 2 diabetes mellitus on bone metabolism and material properties. Endocr Connect. 2019 Mar 01;8(3):R55-R70. PMC free article: PMC6391903 PubMed: 30772871
5. Carrillo-Larco RM, Barengo NC, Albitres-Flores L, Bernabe-Ortiz A. The risk of mortality among people with type 2 diabetes in Latin America: A systematic review and meta-analysis of population-based cohort studies. Diabetes Metab Res Rev. 2019 May;35(4):e3139. PubMed: 30761721
6. Hussain S, Chowdhury TA. The Impact of Comorbidities on the Pharmacological Management of Type 2 Diabetes Mellitus. Drugs. 2019 Feb;79(3):231-242. PubMed: 30742277
7. Kempegowda P, Chandan JS, Abdulrahman S, Chauhan A, Saeed MA. Managing hypertension in people of African origin with diabetes: Evaluation of adherence to NICE Guidelines. Prim Care Diabetes. 2019 Jun;13(3):266-271. PubMed: 30704854
8. Martinez LC, Sherling D, Holley A. The Screening and Prevention of Diabetes Mellitus. Prim Care. 2019 Mar;46(1):41-52. PubMed: 30704659
9. Thewjitcharoen Y, Chotwanvirat P, Jantawan A, Siwasaranond N, Saetung S, Nimitphong H, Himathongkam T, Reutrakul S. Evaluation of Dietary Intakes and Nutritional Knowledge in Thai Patients with Type 2 Diabetes Mellitus. J Diabetes Res. 2018;2018:9152910. PMC free article: PMC6317123 PubMed: 30671482
10. Willis M, Asseburg C, Neslusan C. Conducting and interpreting results of network meta-analyses in type 2 diabetes mellitus: A review of network meta-analyses that include sodium glucose co-transporter 2 inhibitors. Diabetes Res Clin Pract. 2019 Feb;148:222-233. PubMed: 30641163
11. Lai LL, Wan Yusoff WNI, Vethakkan SR, Nik Mustapha NR, Mahadeva S, Chan WK. Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography. J Gastroenterol Hepatol. 2019 Aug;34(8):1396-1403. PubMed: 30551263
12. Eckstein ML, Williams DM, O’Neil LK, Hayes J, Stephens JW, Bracken RM. Physical exercise and non-insulin glucose-lowering therapies in the management of Type 2 diabetes mellitus: a clinical review. Diabet Med. 2019 Mar;36(3):349-358. PubMed: 30536728
13. Massey CN, Feig EH, Duque-Serrano L, Wexler D, Moskowitz JT, Huffman JC. Well-being interventions for individuals with diabetes: A systematic review. Diabetes Res Clin Pract. 2019 Jan;147:118-133. PMC free article: PMC6370485 PubMed: 30500545
14. Shah SR, Iqbal SM, Alweis R, Roark S. A closer look at heart failure in patients with concurrent diabetes mellitus using glucose lowering drugs. Expert Rev Clin Pharmacol. 2019 Jan;12(1):45-52. PubMed: 30488734
15. Chinese Diabetes Society; National Offic for Primary Diabetes Care. [National guidelines for the prevention and control of diabetes in primary care(2018)]. Zhonghua Nei Ke Za Zhi. 2018 Dec 01;57(12):885-893. PubMed: 30486556
16. Petersmann A, Müller-Wieland D, Müller UA, Landgraf R, Nauck M, Freckmann G, Heinemann L, Schleicher E. Definition, Classification and Diagnosis of Diabetes Mellitus. Exp Clin Endocrinol Diabetes. 2019 Dec;127(S 01):S1-S7. PubMed: 31860923
17. Kerner W, Brückel J., German Diabetes Association. Definition, classification and diagnosis of diabetes mellitus. Exp Clin Endocrinol Diabetes. 2014 Jul;122(7):384-6. PubMed: 25014088
18. Cepeda Marte JL, Ruiz-Matuk C, Mota M, Pérez S, Recio N, Hernández D, Fernández J, Porto J, Ramos A. Quality of life and metabolic control in type 2 diabetes mellitus diagnosed individuals. Diabetes Metab Syndr. 2019 Sep-Oct;13(5):2827-2832. PubMed: 31425943
19. Steffensen C, Dekkers OM, Lyhne J, Pedersen BG, Rasmussen F, Rungby J, Poulsen PL, Jørgensen JOL. Hypercortisolism in Newly Diagnosed Type 2 Diabetes: A Prospective Study of 384 Newly Diagnosed Patients. Horm Metab Res. 2019 Jan;51(1):62-68. PubMed: 30522146
20. Qin Z, Zhou K, Li Y, Cheng W, Wang Z, Wang J, Gao F, Yang L, Xu Y, Wu Y, He H, Zhou Y. The atherogenic index of plasma plays an important role in predicting the prognosis of type 2 diabetic subjects undergoing percutaneous coronary intervention: results from an observational cohort study in China. Cardiovasc Diabetol. 2020 Feb 21;19(1):23. PMC free article: PMC7035714 PubMed: 32085772
21. Nowakowska M, Zghebi SS, Ashcroft DM, Buchan I, Chew-Graham C, Holt T, Mallen C, Van Marwijk H, Peek N, Perera-Salazar R, Reeves D, Rutter MK, Weng SF, Qureshi N, Mamas MA, Kontopantelis E. Correction to: The comorbidity burden of type 2 diabetes mellitus: patterns, clusters and predictions from a large English primary care cohort. BMC Med. 2020 Jan 25;18(1):22. PMC free article: PMC6982380 PubMed: 31980024
22. Akalu Y, Birhan A. Peripheral Arterial Disease and Its Associated Factors among Type 2 Diabetes Mellitus Patients at Debre Tabor General Hospital, Northwest Ethiopia. J Diabetes Res. 2020;2020:9419413. PMC free article: PMC7008281 PubMed: 32090126
23. Patoulias D, Papadopoulos C, Stavropoulos K, Zografou I, Doumas M, Karagiannis A. Prognostic value of arterial stiffness measurements in cardiovascular disease, diabetes, and its complications: The potential role of sodium-glucose co-transporter-2 inhibitors. J Clin Hypertens (Greenwich). 2020 Apr;22(4):562-571. PMC free article: PMC8029715 PubMed: 32058679
24. Liakopoulos V, Franzén S, Svensson AM, Miftaraj M, Ottosson J, Näslund I, Gudbjörnsdottir S, Eliasson B. Pros and cons of gastric bypass surgery in individuals with obesity and type 2 diabetes: nationwide, matched, observational cohort study. BMJ Open. 2019 Jan 15;9(1):e023882. PMC free article: PMC6340417 PubMed: 30782717
25. Su YJ, Chen TH, Hsu CY, Chiu WT, Lin YS, Chi CC. Safety of Metformin in Psoriasis Patients With Diabetes Mellitus: A 17-Year Population-Based Real-World Cohort Study. J Clin Endocrinol Metab. 2019 Aug 01;104(8):3279-3286. PubMed: 30779846
26. Choi SE, Berkowitz SA, Yudkin JS, Naci H, Basu S. Personalizing Second-Line Type 2 Diabetes Treatment Selection: Combining Network Meta-analysis, Individualized Risk, and Patient Preferences for Unified Decision Support. Med Decis Making. 2019 Apr;39(3):239-252. PMC free article: PMC6469997 PubMed: 30767632